Skip navigation
  •  Home
  • UDC 
    • Getting started
    • RUC Policies
    • FAQ
    • FAQ on Copyright
    • More information at INFOguias UDC
  • Browse 
    • Communities
    • Browse by:
    • Issue Date
    • Author
    • Title
    • Subject
  • Help
    • español
    • Gallegan
    • English
  • Login
  •  English 
    • Español
    • Galego
    • English
  
View Item 
  •   DSpace Home
  • 1. Investigación
  • Grupos de investigación
  • Unidade de investigación en Enfermidades Infecciosas: Hepatite e SIDA
  • GI-EIHS - Artigos
  • View Item
  •   DSpace Home
  • 1. Investigación
  • Grupos de investigación
  • Unidade de investigación en Enfermidades Infecciosas: Hepatite e SIDA
  • GI-EIHS - Artigos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial

Thumbnail
View/Open
Labarga_Comparision.pdf (258.8Kb)
Use this link to cite
http://hdl.handle.net/2183/21607
Collections
  • GI-EIHS - Artigos [13]
Metadata
Show full item record
Title
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial
Author(s)
Labarga, Pablo
Barreiro, Pablo
Silva, Alfredo da
Guardiola, Josep María
Rubio, Rafael
Aguirrebengoa, Koldo
Miralles, Pilar
Portu, Joseba
Téllez, María Jesús
Morano, Luis
Castro-Iglesias, Ángeles
Pineda, Juan Antonio
Terrón, Alberto
Hernández-Quero, José
Mariño, Ana
Ríos, María José
Echeverría, Santiago
Asensi, Víctor
Vispo, Eugenia
Soriano, Vincent
Date
2012-07-17
Citation
Labraga P, Barreiro P, da Silva A, et al. Comparison of High Ribavirin Induction Versus Standard Ribavirin Dosing, Plus Peginterferon-α for the Treatment of Chronic Hepatitis C in HIV-Infected Patients: The PERICO Trial. J Infect Dis. 2012; 206(6): 961-968
Abstract
[Abstract] BACKGROUND: Ribavirin (RBV) exposure seems to be critical to maximize treatment response in human immunodeficiency virus (HIV)-positive patients with chronic hepatitis C virus (HCV) infection. METHODS: HIV/HCV-coinfected individuals naive to interferon were prospectively randomized to receive peginterferon-α-2a (180 μg/d) plus either RBV standard dosing (1000 or 1200 mg/d if <75 or ≥ 75 kg, respectively) or RBV induction (2000 mg/d) along with subcutaneous erythropoietin β (450 IU/kg/wk), both during the first 4 weeks, followed by standard RBV dosing until completion of therapy. Early stopping rules at weeks 12 and 24 were applied in patients with suboptimal virological response. RESULTS: A total of 357 patients received ≥ 1 dose of the study medication. No differences in main baseline characteristics were found when comparing treatment arms. Sustained virological response (SVR) was attained by 160 (45%) patients, with no significant differences between RBV induction and standard treatment arms (SVR in 72 of 169 patients [43%] vs 88 of 188 [47%], respectively). At week 4, undetectable HCV RNA (29% vs 25%) and mean RBV trough concentration (2.48 vs 2.14 μg/mL) were comparable in both arms, whereas mean hemoglobin decay was less pronounced in the RBV induction plus erythropoietin arm than in the RBV standard dosing arm (-1.7 vs -2.3 mg/dL; P < .005). Treatment discontinuation occurred in 91 (25%) patients owing to nonresponse and in 29 (8%) owing to adverse events. HCV relapse occurred in 34 patients (10%). Univariate and multivariate analyses identified HCV genotype 2 or 3 (odds ratio [OR], 10.3; 95% confidence interval [CI], 2.08-50.2; P = .004), IL28B CC variants (OR, 2.92; 95% CI, 1.33-6.41; P = .007), nonadvanced liver fibrosis (OR, 2.27; 95% CI, 1.06-5.01; P = .03), and rapid virological response (OR, 40.3; 95% CI, 5.1-314.1; P < .001) as predictors of SVR. CONCLUSIONS: A 4-week course of induction therapy with high RBV dosing along with erythropoietin does not improve SVR rates in HIV/HCV-coinfected patients. Preemptive erythropoietin might blunt the benefit of RBV overdosing by enhancing erythrocyte uptake of plasma RBV.
Keywords
Antiretroviral therapy, highly active
Antiviral agents
Dose-Response Relationship
Drug Therapy - Combination
HIV Infection
Hepacivirus
Hepatitis C
Interferon-alpha
Polyethylene Glycols
RNA viral
Recombinant proteins
Ribavirin
 
Editor version
https://doi.org/10.1093/infdis/jis449
Rights
This is a pre-copyedited, author-produced version of an article accepted for publication in The Journal of Infectiuos Diseases following peer review. The version of record is avaliable online at Oxford Academic web.
ISSN
0022-1899

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

View Usage Statistics
Sherpa
OpenArchives
OAIster
Scholar Google
UNIVERSIDADE DA CORUÑA. Servizo de Biblioteca.    DSpace Software Copyright © 2002-2013 Duraspace - Send Feedback